Successful Romandie Networking Event

ADCs in the Spotlight at Swiss HLG’s Romandie Networking Event
On the 25th September, we had the pleasure of hosting our annual Romandie networking event in partnership with Debiopharm, who welcomed us to their Lausanne headquarters.

The evening focused on the exciting world of antibody–drug conjugates (ADCs) — a modality that’s rapidly transforming targeted therapies. Our speakers delivered powerful insights:
Bjoern M Hock presented Tubulis’ cutting-edge ADC technologies and portfolio.
Sophie Brachet & Ilona Kotala showcased Debiopharm’s innovative linker technologies and strategic pipeline development.
Filippo Mulinacci shared the inspiring journey of Araris, from academic roots to a >$1B preclinical-stage exit.
Peters Solange offered a deep dive into the lung cancer treatment landscape and the promise of ADCs in oncology.

The evening concluded with a relaxed happy hour, sparking great conversations and new connections.

Key takeaway: With advances in antibody engineering, multi-specific design, payload innovation, and linker technologies, ADCs are not just a trend — they’re here to stay.

Thank you to all who joined us and made the event a success!